Start a Conversation

Pet Pharmaceuticals welcomes discussions with investors, pharmaceutical and animal-health companies, research organisations, scientific collaborators and other parties interested in the development of differentiated pharmaceutical medicines.

Whether you are exploring an investment opportunity, a strategic partnership, a licensing discussion or a scientific collaboration, we would be pleased to hear from you.

Investment Enquiries

Pet Pharmaceuticals is seeking strategic investment to advance its initial portfolio of six therapeutic programmes and strengthen the Integrated Scientific Discovery Capability that supports their development.

For further information about the investment opportunity, please contact us to request access to the Company’s investment materials or arrange an introductory discussion.

Strategic Partnerships and Licensing

Our business model is designed to create pharmaceutical assets capable of progressing through strategic partnerships, licensing, co-development and asset monetisation.

We welcome discussions with pharmaceutical and animal-health companies interested in:

programme-specific licensing;
co-development opportunities;
research and development partnerships;
territorial or indication-based rights;
platform-enabled discovery collaborations; and
broader strategic relationships.

Scientific and Research Collaboration

Pet Pharmaceuticals works with internationally recognised scientific, veterinary and pharmaceutical experts to support the discovery and development of pharmaceutical-grade multi-pathway combination phytopharmaceutical medicines.

We welcome appropriate enquiries from universities, research institutions, clinical specialists, laboratories and organisations with complementary scientific capabilities.

General Enquiries

For corporate, media, recruitment or other general enquiries, please contact the Pet Pharmaceuticals team.

Contact Details

View LinkedIn Profile

Name

Organisation

Position

Phone

Nature of enquiry

Message

Pet Pharmaceuticals is building the scientific capability, therapeutic portfolio and strategic relationships required to establish a new class of pharmaceutical medicines.

We welcome conversations with organisations and individuals who share our ambition to create safer, more effective medicines for chronic and complex diseases.